NCT04733040: An ongoing trial by HI-Bio, A Biogen Company
This trial is completed, but has been granted a delay in reporting its results.
It must report results 8 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04733040 |
|---|---|
| Title | A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 20, 2021 |
| Completion date | Dec. 14, 2023 |
| Required reporting date | Dec. 14, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |